Effects of disease‑modifying anti‑rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: A systematic review and meta‑analysis
Clin Rheumatol 2024;43(3):1045–1052 doi: 10.1007/s10067-023-06849-5
The results of the meta-analysis show that TNFi, IL-17i, and JAK inhibitor treatments significantly improved sacroiliac joint SPARCC scores in patients with axSpA or AS at Weeks 12–16. However, there were no significant differences in mean improvement between the treatment groups.
Hansmaennel, et al. pooled the results of 18 studies, with nine investigating TNFis, three investigating IL-17is and four investigating JAKis. Six studies included patients with AS, while 12 studies specifically included patients with axSpA.
